One in four patients with IIM will develop cancer within 3 years of their diagnosis, particularly individuals with the myositis-specific autoantibodies such as transcriptional intermediary factor 1-gamma (anti-TIF1γ) and anti-nuclear matrix protein 2 (anti-NXP2).7 Here, TRIM33 is linked to myositis disease.